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Rocuronium and Malignant Hyperthermia 
We thank Drs. Schuster and Johannsen for their interest in these complex cases and concur that 
there were several possible etiologies for the described reactions. We addressed these in the 
discussion portion of our report.  
Although the use of genetic or caffeine–halothane contracture testing would have been ideal, the 
tests were not considered feasible to perform in the community hospital where these patients were 
treated. Genetic testing would not have changed the course of therapy, as both patients experienced 
resolution of hyperthermia on discontinuation of the suspected offending agent. The caffeine–
halothane contracture test has a number of associated constraints, including limited availability of 
testing centers in the United States and requirements for patients to travel to these centers for 
testing. Both tests may burden patients with substantial costs, estimated at $800–$4000 for genetic 
testing and at least $6000 for the caffeine–halothane contracture test.1 
We agree that previously described instances of malignant hyperthermia (MH) associated with 
nondepolarizing neuromuscular blockers could have been explained by other offending agents; we 
discussed this point in our report. We appreciate and share Drs. Schuster and Johannsen's concerns 
regarding the potential clinical implications of the development of MH in association with 
nondepolarizing neuromuscular blockers, particularly in patients known to be susceptible to such 
a reaction.  
Case reports are open to interpretation by readers, who are responsible for considering the rare and 
perplexing circumstances of the cases, the limitations of the reports, and the implications of the 
reports on practice. It is the responsibility of authors to help maximize medication safety by sharing 
these cases, which will better allow health care providers to respond appropriately if they encounter 
similar scenarios in clinical practice.  
Jennifer Quinn McCann, Pharm.D., BCPS 
Ashton E. Beggs, Pharm.D. 
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